Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
This is the complete answer, not a partial one — the list is never padded.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Claire Mazumdar | $625,000 | $0 | $0 | $0 | $292,188 | $0 | $10,500 | $927,688 |
| Chief Executive Officer | ||||||||
| Ryan Cohlhepp | 588,000 | 10,000 | 0 | 0 | 249,900 | 0 | 10,500 | 858,400 |
| President and Chief Operating Officer | ||||||||
| David Raben | 525,000 | 5,000 | 0 | 0 | 170,625 | 0 | 8,539 | 709,164 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Claire Mazumdar | $927,688 | — | — | — |
| Ryan Cohlhepp | 858,400 | — | — | — |
| David Raben | 709,164 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
No insider equity transactions reported since the proxy statement.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Claire Mazumdar | Option | 90,981 | 4.1 | — |
| Claire Mazumdar | Option | 8,334 | 4.1 | — |
| Claire Mazumdar | Option | 16,227 | 4.44 | — |
| Claire Mazumdar | Option | 68,965 | 3.79 | — |
| Claire Mazumdar | Option | 163,050 | 3.79 | — |
| Claire Mazumdar | Option | 353,287 | 9.24 | — |
| Claire Mazumdar | Option | 297,504 | 5.45 | — |
| Claire Mazumdar | Option | 784,672 | 9.24 | — |
| Claire Mazumdar | Option | 3,126 | 4.1 | — |
| Claire Mazumdar | Option | 17,710 | 4.1 | — |
| Claire Mazumdar | Option | 44,625 | 3.79 | — |
| Claire Mazumdar | Option | 106,254 | 3.79 | — |
| Claire Mazumdar | Option | 189,320 | 5.45 | — |
| David Raben | Option | 66,004 | 3.79 | — |
| David Raben | Option | 37,863 | 3.79 | — |
| David Raben | Option | 77,080 | 5.45 | — |
| David Raben | Option | 148,753 | 9.24 | — |
The company targets a general competitive position based on independent third-party benchmark analytics to inform the mix of base salary, bonus, and long-term incentives. The program is designed to motivate employees to achieve short- and long-term results in the best interests of stockholders and to promote executive retention through equity grants.
| CEO STI target (% of salary) | NaN% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | The company maintains a compensation recovery policy (clawback policy) in accordance with SEC and Nasdaq listing rules, requiring the recovery of incentive-based compensation in the event of a financial restatement due to material noncompliance. |
| Anti-hedging | The insider trading policy expressly prohibits derivative transactions of company stock by executive officers, directors, and employees, including purchases of derivative securities that provide the economic equivalent of ownership. |
| Anti-pledging | — |
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 15,000 / 10,000 / 8,000 |
| Stock ownership guideline | — |
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bicara Therapeutics | 2025 | Claire Mazumdar | $625,000 | $0 | $0 | $292,188 | $927,688 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Claire Mazumdar | DEF 14A | 2026-04-27 | 0001628280-26-027320 | Section “Executive Compensation”. As printed: 927,688. Filing ↗machine: r2 · c21 · span 297846–297853 |
| 2 | Section 01, Ryan Cohlhepp | DEF 14A | 2026-04-27 | 0001628280-26-027320 | Section “Executive Compensation”. As printed: 858,400. Filing ↗machine: r4 · c21 · span 301875–301882 |
| 3 | Section 01, David Raben | DEF 14A | 2026-04-27 | 0001628280-26-027320 | Section “Executive Compensation”. As printed: 709,164. Filing ↗machine: r6 · c21 · span 306020–306027 |
| 4 | Section 07, pay ratio | 10-K | 2026-03-30 | 0001628280-26-022010 | Section “CEO Pay Ratio”. As printed: —. Filing ↗ |
| 5 | Bicara Therapeutics (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027320 | CEO total compensation as printed in Bicara Therapeutics's own proxy. As printed: 927,688. Filing ↗machine: r2 · c21 · span 297846–297853 |